ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SNGX Soligenix Inc

0.43
-0.042 (-8.90%)
Apr 17 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,413,665
Bid Price 0.425
Ask Price 0.43
News -
Day High 0.5421

Low
0.3705

52 Week Range

High
4.20

Day Low 0.44
Company Name Stock Ticker Symbol Market Type
Soligenix Inc SNGX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.042 -8.90% 0.43 19:58:30
Open Price Low Price High Price Close Price Prev Close
0.481 0.44 0.5421 0.51 0.472
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
11,026 4,413,665 $ 0.4871882 $ 2,150,286 - 0.3705 - 4.20
Last Trade Time Type Quantity Stock Price Currency
19:58:30 formt 300 $ 0.43 USD

Soligenix Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.29M 10.38M - 839k -6.14M -0.59 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Soligenix News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SNGX Message Board. Create One! See More Posts on SNGX Message Board See More Message Board Posts

Historical SNGX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.460.93220.37050.469091128,822,983-0.03-6.52%
1 Month0.640.93220.37050.46977657,709,454-0.21-32.81%
3 Months0.60470.93220.37050.47598282,597,248-0.1747-28.89%
6 Months0.52512.000.37050.71434292,719,814-0.0951-18.11%
1 Year1.594.200.37050.86314841,621,445-1.16-72.96%
3 Years20.1024.000.37056.10863,049-19.67-97.86%
5 Years12.7555.200.370515.57936,784-12.32-96.63%

Soligenix Description

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Your Recent History

Delayed Upgrade Clock